CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab

With CANTOS, Novartis's canakinumab has become the first investigational treatment to show that selectively targeting inflammation significantly reduces cardiovascular risk, albeit modestly, but with the added bonus of reducing lung cancer.

3d rendering Human Heart — • Source: Shutterstock

Reducing inflammation with Novartis AG's canakinumab (ACZ885) can lower the risk of lung cancer as well as cardiovascular disease, the full data from the CANTOS study show. Its researchers say the findings are a validation of the inflammation hypothesis in atherosclerosis, ushering in a "third era" in cardiovascular disease prevention, and at the same time open up new possibilities in cancer treatment.

In June, observers expressed surprise when the top-line data from the 10,000-patient CANTOS study proved positive, showing the anti-IL1β monoclonal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

Oct 08 2025

• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

Oct 08 2025

• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

Oct 08 2025

• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

Oct 07 2025

• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

Oct 07 2025

• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.